orforglipron
An oral, non-peptide glucagon-like peptide-1 receptor agonist
Networked: 7
relevant articles (1 outcomes,
4 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
1. | Type 2 Diabetes Mellitus (MODY)
01/01/2023
- " Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study." 01/01/2023
- " We assessed the efficacy and safety of orforglipron versus placebo or dulaglutide in participants with type 2 diabetes. " 12/01/2023
- " Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials." 12/01/2023
- " The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatment of type 2 diabetes mellitus (T2DM), obesity or both. " 01/01/2023
- " Orforglipron, an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist, is in development for type 2 diabetes and obesity. "
|
2. | Obesity
|
3. | Weight Loss (Weight Reduction)
|
4. | Body Weight (Weight, Body)
|
5. | Overweight
|
|
Related Drugs and Biologics
Related Therapies and Procedures